Nurix Therapeutics Inc
Nurix Therapeutics Inc
NRIX

Nurix Therapeutics Inc (NRIX)

$12.517.84%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$11.01
Day's Range
$12.56
$7.52
52-Week Range
$37.42
1 month return14.97%
3 month return17.2%
1 year return51.67%
5 year return38.98%

Company Information

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.
OrganizationNurix Therapeutics Inc
Employees2020
CEO
IndustryHealth Technology

Analyst Recommendation

based on 16 analysts ratings

Buy
87%
Buy
12%
Hold
0%
Sell

Based on 16 Wall street analysts offering stock ratings for Nurix Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 252.76%

Current

$12.51

Target

$44.13

Recommendation Trend

Based on 16 analyst

Current1M Ago3M Ago
Buy
14
14
13
Hold
2
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
526.8M
Book Value
7.66
Dividend Share
0.0
Dividend Yield
0.0
Earnings Share
-2.73
Wall Street Target Price
44.3

Valuation

Trailing PE0.0
Forward PE0.0
Price/Sales (ttm)
17.71
Price/Book (mrq)
1.84
Enterprise Value
317.9M
Enterprise Value/Revenue
9.25
Enterprise Value/Ebitda
0.0

Technicals

50 Day MA
14.17
200 Day MA
25.29

Institutional Holdings

T. Rowe Price Associates, Inc.

10.69%

Redmile Group, LLC

6.72%

BlackRock Inc

5.67%

Baker Bros Advisors LP

5.46%

TRV GP III, LLC

5.39%

State Street Corporation

5.12%

Discover more

Frequently Asked Questions

What is Nurix Therapeutics Inc share price today?

Can Indians buy Nurix Therapeutics Inc shares?

How can I buy Nurix Therapeutics Inc shares from India?

Can Fractional shares of Nurix Therapeutics Inc be purchased?

What are the documents required to start investing in Nurix Therapeutics Inc stocks?

What are today’s High and Low prices of Nurix Therapeutics Inc?

What are today’s traded volumes of Nurix Therapeutics Inc?

What is today’s market capitalisation of Nurix Therapeutics Inc?

What is the 52 Week High and Low Range of Nurix Therapeutics Inc?

How much percentage Nurix Therapeutics Inc is down from its 52 Week High?

How much percentage Nurix Therapeutics Inc is up from its 52 Week low?

What are the historical returns of Nurix Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of Nurix Therapeutics Inc?